PT Jayamas Medica Industri Tbk (ISX:OMED) EBITDA per Share: Rp19.59 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:OMED PT Jayamas Medica Industri Tbk ISX:OMED
90 GF Score
Price Rp208.00
GF Value Rp238.52
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is PT Jayamas Medica Industri Tbk EBITDA per Share?

PT Jayamas Medica Industri Tbk ISX:OMED +2.97% 90 EBITDA per Share is Rp19.59 as of Mar. 2026. GuruFocus rates ISX:OMED with a GF Score™ of 90/100 and a GF Value™ of Rp238.52 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 692 Medical Devices & Instruments companies, PT Jayamas Medica Industri Tbk ranks worse than 53.18% on this metric.

PT Jayamas Medica Industri Tbk's EBITDA per Share for the three months ended in Mar. 2026 was Rp5.13. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was Rp19.59.

During the past 12 months, the average EBITDA per Share Growth Rate of PT Jayamas Medica Industri Tbk was 18.90% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 6.00% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for PT Jayamas Medica Industri Tbk's EBITDA per Share or its related term are showing as below:

ISX:OMED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.8   Med: -5.7   Max: 11.1
Current: 6

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of PT Jayamas Medica Industri Tbk was 11.10% per year. The lowest was -24.80% per year. And the median was -5.70% per year.

ISX:OMED's 3-Year EBITDA Growth Rate is ranked worse than
53.18% of 692 companies
in the Medical Devices & Instruments industry
Industry Median: 7.65 vs ISX:OMED: 6.00

PT Jayamas Medica Industri Tbk's EBITDA for the three months ended in Mar. 2026 was Rp138,512 Mil.

During the past 12 months, the average EBITDA Growth Rate of PT Jayamas Medica Industri Tbk was 18.80% per year. During the past 3 years, the average EBITDA Growth Rate was 6.00% per year. During the past 5 years, the average EBITDA Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of PT Jayamas Medica Industri Tbk was 11.10% per year. The lowest was -24.80% per year. And the median was -5.70% per year.


PT Jayamas Medica Industri Tbk  (ISX:OMED) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


PT Jayamas Medica Industri Tbk EBITDA per Share Related Terms


PT Jayamas Medica Industri Tbk EBITDA per Share Historical Data

* Premium members only.

The historical data trend for PT Jayamas Medica Industri Tbk's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Jayamas Medica Industri Tbk EBITDA per Share Chart

PT Jayamas Medica Industri Tbk Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial 28.39 15.36 13.70 16.02 18.29

PT Jayamas Medica Industri Tbk Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 4.01 4.98 5.48 5.13
ISX:OMED
90GF Score
PT Jayamas Medica Industri Tbk ISX:OMED
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Jayamas Medica Industri Tbk EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

PT Jayamas Medica Industri Tbk's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=494461.842/27040.833
=18.29

PT Jayamas Medica Industri Tbk's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=138511.964/27008.120
=5.13

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp19.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of Rp19.59 mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a EBITDA per Share of Rp19.59 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on PT Jayamas Medica Industri Tbk and its competitors. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #368 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is PT Jayamas Medica Industri Tbk's EBITDA per Share too high?
PT Jayamas Medica Industri Tbk's current EBITDA per Share is Rp19.59. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #368 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's EBITDA per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #368 out of 692 companies for EBITDA per Share. This places PT Jayamas Medica Industri Tbk in the lower half of its industry. The industry median EBITDA per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on PT Jayamas Medica Industri Tbk and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current EBITDA per Share is Rp19.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp238.52, compared to a current price of Rp208.00 — trading 12.8% below its estimated fair value. The current EBITDA per Share is Rp19.59. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current EBITDA per Share is Rp19.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?

Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued. The current stock price of Rp208.00 is trading 12.8% below its estimated GF Value™ of Rp238.52. GuruFocus considers PT Jayamas Medica Industri Tbk to be Modestly Undervalued.

Key valuation signals for ISX:OMED:

  • EBITDA per Share: Rp19.59
  • GF Value™: Rp238.52 vs. price of Rp208.00 (12.8% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Jayamas Medica Industri Tbk Business Description

Address Sebelah Selatan Jalan By Pass RT 05 / RW 01, Sidomojo Village, Krian District, Sidoarjo, Jawa Timur, East Java, IDN, 61262
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score

Get the complete analysis for ISX:OMED

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp208.00
Price
Rp238.52
GF Value